Mustang Bio, Inc.
NASDAQ: MBIO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Manuel Litchman
- Employees
- 4
- Headquarters
- Waltham, United States
- IPO year
- 2017
- Market cap
- $5.3M
- Website
- https://www.mustangbio.com
Loading MBIO…
Loading profile data…Frequently asked questions about MBIO
What does Mustang Bio, Inc. (MBIO) do?
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chron...
Where does MBIO trade?
Mustang Bio, Inc. (MBIO) trades on the NASDAQ.
What sector is MBIO in?
Mustang Bio, Inc. (MBIO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Mustang Bio, Inc.?
Manuel Litchman is the chief executive officer of Mustang Bio, Inc. (MBIO).
Where is Mustang Bio, Inc. headquartered?
Mustang Bio, Inc. is headquartered in United States.
Does MBIO pay a dividend?
Mustang Bio, Inc. (MBIO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MBIO go public?
Mustang Bio, Inc. (MBIO) completed its initial public offering in 2017.